M&A Deal Summary

NuvinkaDx Acquires ALPCO

On April 21, 2022, NuvinkaDx acquired distribution company ALPCO from Ampersand Capital Partners

Acquisition Highlights
  • This is NuvinkaDx’s 1st transaction in the Distribution sector.
  • This is NuvinkaDx’s 1st transaction in the United States.
  • This is NuvinkaDx’s 1st transaction in New Hampshire.

M&A Deal Summary
Date 2022-04-21
Target ALPCO
Sector Distribution
Buyer(s) NuvinkaDx
Sellers(s) Ampersand Capital Partners
Deal Type Merger

Target

ALPCO

Salem, New Hampshire, United States
ALPCO is an importer and distributor of immunoassay-based products for the North American life science markets. ALPCO is a provider of proprietary and distributed diagnostics solutions, with over 60 collaborating partners from around the globe. ALPCO was founded in 1990 and is based in Salem, New Hampshire.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

NuvinkaDx

Salem, New Hampshire, United States
Category Company
Sector Life Science
DESCRIPTION

NuvinkaDx is a global diagnostics company, brings established expertise in immunodiagnostics and molecular diagnostics. NuvinkaDx is based in Salem, New Hampshire.

DEAL STATS #
Overall 2 of 2
Sector (Distribution) 1 of 1
Type (Merger) 2 of 2
State (New Hampshire) 1 of 1
Country (United States) 1 of 1
Year (2022) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-04-21 GeneProof

Brno, Czech Republic

GeneProof is a molecular diagnostics company. GeneProof is a producer of PCR reagents and distributes its portfolio of more than 70 CE-marked molecular diagnostic tests and instruments throughout Europe, Africa, the Middle East, and South America. GeneProof was founded in 2005 and is based in Brno, Czech Republic.

Buy -

Seller(S) 1

SELLER

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 52 of 55
Sector (Distribution) 1 of 1
Type (Merger) 4 of 4
State (New Hampshire) 1 of 1
Country (United States) 50 of 51
Year (2022) 5 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-04-21 NuvinkaDx

Salem, New Hampshire, United States

NuvinkaDx is a global diagnostics company, brings established expertise in immunodiagnostics and molecular diagnostics. NuvinkaDx is based in Salem, New Hampshire.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-06-02 Vernal Biosciences

Colchester, Vermont, United States

Vernal Biosciences provides mRNA and LNP-mRNA manufacturing services to democratize the use of mRNA for all use cases ranging from drug discovery to clinical development across all use cases such as gene editing and regulation, cellular programming, vaccines, mRNA replacement, oncology, autoimmune, and protein degradation. Vernal Biosciences is based in Colchester, Vermont.

Buy -
Mergr

Product

Company

Legal